Intravesical bacille Calmette-Guérin therapy for muscle invasive bladder cancer

Non-muscle invasive bladder cancer (NMIBC) is a heterogeneous population of tumours accounting for 80% of bladder cancers. Over the years, the management of this disease has been changing with improvements in results and outcomes. In this review, we focus on the latest updates on the management of NMIBC.Can Urol Assoc J 2010;4(1):56-64 RésuméLe cancer de la vessie sans envahissement musculaire est un groupe hétérogène de tumeurs représentant 80 % des cancers de la vessie. Au fil des années, la prise en charge de cette maladie a évolué, et les résultats et issues thérapeutiques se sont améliorés. Dans l'article qui suit, nous présentons les plus récents développe-ments dans la prise en charge de ce type de cancer.

show abstract

“…It is not recommended for muscle-invasive tumours, as up to 77% of such patients will develop systemic disease when treated with BCG. 93 …”

Section: Efficacymentioning

confidence: 99%

Update on the management of non-muscle invasive bladder cancer

Aldousari

Kassouf

2013

CUAJ

View full text Add to dashboard Cite

show abstract

“…Success rates of 60–70% have been reported [ 105, 106]. Intravesical BCG therapy for the treatment of muscle‐invasive TCC of the bladder is ineffective [ 107].…”

Section: Clinical Resultsmentioning

confidence: 99%

Bacille Calmette‐Guérin in superficial transitional cell carcinoma

Mungan

Witjes

1998

British Journal of Urology

View full text Add to dashboard Cite

“…Fleischman et al [14] found no significant correlation between superficial tumor FN expression and a favorable clinical response to BCG, but the correlation was significant between the degree of normal mucosa FN expression and the subsequent clinical course. Rosenbaum et al [15] have shown that FN expression in the bladder of patients with invasive disease (T2-T4) does also not correlate significantly with the clinical response to BCG therapy.…”

Section: Discussionmentioning

confidence: 99%

Urinary Fibronectin Levels in Patients Treated with Intravesical Bacillus Calmette-Guérin for Superficial Bladder Cancer

Danışman¹,

Bulut²,

Kukul³

et al. 2000

Urol Int

View full text Add to dashboard Cite

Intravesical bacillus Calmette-Guérin (BCG) has been shown to be an effective treatment for superficial transitional cell carcinoma (TCC) of the bladder, but the precise mechanism of action of BCG remains poorly understood. Fibronectin (FN), an important component of the extracellular matrix, has been found to play a role in BCG therapy. Some studies have shown that the soluble form of FN can compete efficiently with the matrix form of binding to the specific receptors on the bacteria and could consequently diminish the effect of BCG treatment. To evaluate a possible correlation between the urinary levels of FN and the efficacy of BCG therapy, we determined prospectively the urinary FN levels in 38 patients with TCC of the bladder and in 25 control subjects without malignancy matched for age and sex. All TCC patients were treated with transurethral tumor resection plus 6 weekly intravesical BCG instillations. After an average follow-up of 30 months, 8 patients (21.1%) had recurrent tumors, while 30 (78.9%) were free of tumor after intravesical BCG therapy. Urinary levels of FN in cancer patients have been shown to be significantly higher than controls (p < 0.001). These elevated levels were not decreased significantly after the operation (p > 0.05). It was also found that the mean urinary FN levels were not statistically significant between patients with recurrence and complete remission. The data suggest that BCG-bladder tumor cell binding is not influenced by soluble fibronectin and urinary FN may not be a ideal marker for selecting patients to BCG therapy.

show abstract

Intravesical bacille Calmette-Guérin therapy for muscle invasive bladder cancer

Cited by 13 publications

References 17 publications

Update on the management of non-muscle invasive bladder cancer

Update on the management of non-muscle invasive bladder cancer

Bacille Calmette‐Guérin in superficial transitional cell carcinoma

Urinary Fibronectin Levels in Patients Treated with Intravesical Bacillus Calmette-Guérin for Superficial Bladder Cancer

Contact Info

Product

Resources

About